Ind-Swift Laboratories Limited (NSE:INDSWFTLAB)

Market Cap	10.12B
Revenue (ttm)	5.67B
Net Income (ttm)	2.30B
Shares Out	93.46M
EPS (ttm)	31.48
PE Ratio	3.44
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,902
Average Volume	46,420
Open	111.90
Previous Close	110.17
Day's Range	107.10 - 111.90
52-Week Range	68.72 - 149.00
Beta	0.44
RSI	62.15
Earnings Date	Nov 7, 2025

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 47
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INDSWFTLAB

Financial Performance

In 2024, Ind-Swift Laboratories's revenue was 5.62 billion, a decrease of -56.70% compared to the previous year's 12.97 billion. Earnings were 2.50 billion, a decrease of -40.50%.